FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
Centre Léon Bérard
Lyon, FranciaPublicaciones en colaboración con investigadores/as de Centre Léon Bérard (5)
2024
-
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis
European Journal of Cancer, Vol. 202
-
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Nature Medicine, Vol. 30, Núm. 8, pp. 2208-2215
2023
-
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
Future oncology (London, England), Vol. 19, Núm. 35, pp. 2349-2359
2017
-
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
Breast Cancer Research and Treatment, Vol. 165, Núm. 3, pp. 601-609
2015
-
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710